Fractyl Health, Inc.’s Lock-Up Period Set To Expire on July 31st (NASDAQ:GUTS)

Fractyl Health’s (NASDAQ:GUTS) lock-up period is set to expire on Wednesday, July 31st. Fractyl Health had issued 7,333,333 shares in its IPO on February 2nd. The total size of the offering was $109,999,995 based on an initial share price of $15.00. After the end of Fractyl Health’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Fractyl Health Stock Performance

Shares of Fractyl Health stock opened at $4.19 on Friday. The stock’s fifty day moving average price is $5.38. The company has a quick ratio of 9.37, a current ratio of 9.38 and a debt-to-equity ratio of 0.34. Fractyl Health has a one year low of $3.77 and a one year high of $14.50.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.45). The company had revenue of $0.03 million for the quarter. On average, equities research analysts forecast that Fractyl Health will post -2.03 earnings per share for the current fiscal year.

Institutional Trading of Fractyl Health

A hedge fund recently bought a new stake in Fractyl Health stock. American International Group Inc. bought a new stake in Fractyl Health, Inc. (NASDAQ:GUTS) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,339,261 shares of the company’s stock, valued at approximately $9,911,000. American International Group Inc. owned 2.80% of Fractyl Health as of its most recent filing with the Securities & Exchange Commission.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.